# EMMA-1 (Erbitux for Multiple Myeloma)

> **NCT00368121** · PHASE2 · TERMINATED · sponsor: **Prof. Dr. Andreas Engert** · enrollment: 13 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cetuximab +/- Dexamethasone

## Key facts

- **NCT ID:** NCT00368121
- **Lead sponsor:** Prof. Dr. Andreas Engert
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-08
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Lack of recruitable patients
- **Last updated:** 2012-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00368121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00368121, "EMMA-1 (Erbitux for Multiple Myeloma)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00368121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*